• I C Nitu-Whalley, A Griffioen, C Harrington, and C A Lee.
• Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, Pond Street, London, United Kingdom. iona@rfhsm.ac.uk
• Am. J. Hematol. 2001 Apr 1;66(4):280-4.

AbstractLimited data are available regarding optimal treatment with desmopressin (DDAVP) or intermediate-purity FVIII concentrates rich in VWF (CFCs) in patients with von Willebrand disease (VWD) who undergo planned surgery. We undertook a retrospective review over 10 years (1988-1997) and identified 27 patients treated with DDAVP for 35 surgical events and 38 patients who received CFCs for 68 elective surgical events. Tranexamic acid was usually added for mucosal surgery. The FVIII:C levels and the severity of surgery were used to determine the frequency and the doses of postoperative treatment. For major surgery the median pre- and post-operative doses of CFCs were 54 and 43 IU/kg, respectively, and for minor surgery the median doses varied between 34 and 52 IU/kg preoperatively and between 23 and 37 IU/kg postoperatively. The effectiveness of haemostasis was excellent in 32 events (91%) treated with DDAVP and in 56 events (82%) treated with CFCs. It is concluded that patients with VWD do not carry an increased operative risk if appropriate therapy is given.Copyright 2001 Wiley-Liss, Inc.

36 keywords...

hide…